CLAIM AMENDMENTS

- (Currently amended) A method of blocking microbial adherence to a
 eukaryotic cell surface in a mammal by applying to said surface a pharmacologically acceptable composition comprising consisting essentially of
 isoleucine present in a microbial blocking quantity.
- 2. (Original) The method of claim 1 wherein the microbial blocking quantity is in the range of from about 0.1 ug/cm² to about 1 gm/cm² of eukaryotic cell surface area.
- 3. (Original) The method of claim 2 wherein said quantity is from about 3 ug/cm² to about 100 ug/cm².
- 4. (Original) The method of claim 2 wherein said quantity is from about 10 ug/cm² to about 100 ug/cm².
- 5. (Original) The method of claim 1 wherein the mammal is man.
- 6. (Original) The method of claim 1 wherein the epithelial surface is one or more of the oral cavity, GI tract, respiratory tract, genitourinary tract, skin, eye, and vaginal/cervical area.
- 7. (Original) The method of claim 1 wherein the composition consists of a pure powder of L(+)-isoleucine and/or DL-isoleucine.
- 8. (Original) The method of claim 1 wherein the composition is in the form of a dry powder, a paste, a solution, a gel, a tablet, a lozenge, or a capsule.
- (Previously amended) The method of claim 1 wherein the composition is directly applied to the epithelial said surface.

- 10. (Previously amended) The method of claim 1 wherein the composition is in the form of a pharmacologically acceptable aqueous composition containing from about 0.01 ug/ml to about 50 ug/ml of isoleucine.
- 11. (Previously amended) A pharmacologically acceptable composition comprising :
 - A) from about 0.001 to about 99% by weight of a compound consisting essentially of isoleucine;
 - B) at least one additional pharmacologically active substance; and, optionally,
 - C) pharmacologically acceptable carrier materials and/or excipients.
- 12. (Original) The composition of claim 11 wherein component A) is present in from about 0.002 to about 50% by weight.
- 13. (Original) The composition of claim 11 wherein component A) is present in from about 0.1 to about 25% by weight.
- 14. (Original) The composition of claim 11 wherein said composition is in the form of a dental care product.
- 15. (Original) The composition of claim 14 wherein component B) is one or more of a fluoride, xylitol, an antibody, and an anti-microbial agent.
- 16. (Original) The composition of claim 14 wherein the composition is in the form of a toothpaste or a gel.
- 17. (Cancelled)

- 18. (Previously amended) A toothpaste or gel comprising a eukaryotic cell surface blocking quantity of a compound consisting essentially of isoleucine.
- 19-24 (Cancelled)
- 25. (Currently amended) The composition of claim 24_11 wherein componentB) is an antifungal and/or antimicrobial substance.
- 26-30 (Cancelled)
- 31. (Previously amended) The composition of claim 11 wherein the composition is in the form of a wound ointment or cream, and component B) is one or more of an antimicrobial substance and an anesthetic.
- 32. (Previously amended) A wound ointment or cream comprising a eukaryotic cell surface blocking quantity of a compound consisting essentially of isoleucine.
- 33. (Cancelled)
- 34. (Original) The composition of claim 11 wherein the composition is in the form of a skin ointment or cream.
- 35-40 (Cancelled)